{"name":"Groupe Oncologie Radiotherapie Tete et Cou","slug":"groupe-oncologie-radiotherapie-tete-et-cou","ticker":"","exchange":"","domain":"","description":"Groupe Oncologie Radiotherapie Tete et Cou is a specialized oncology company focused on the development and treatment of head and neck cancers. The company has a robust pipeline with 14 drugs in various stages of clinical development, including several in Phase 2 and Phase 3 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"5-Fluorouracile","genericName":"5-Fluorouracile","slug":"5-fluorouracile","indication":"Colorectal cancer","status":"marketed"},{"name":"Carbo, 5FU, Cetuximab","genericName":"Carbo, 5FU, Cetuximab","slug":"carbo-5fu-cetuximab","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"Carboplatin, 5FU concomitant","genericName":"Carboplatin, 5FU concomitant","slug":"carboplatin-5fu-concomitant","indication":"Head and neck cancer (squamous cell carcinoma)","status":"phase_3"},{"name":"concomitant cisplatin","genericName":"concomitant cisplatin","slug":"concomitant-cisplatin","indication":"Ovarian cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Ethyol","genericName":"Ethyol","slug":"ethyol","indication":"Other","status":"marketed"},{"name":"Ligufalimab","genericName":"Ligufalimab","slug":"ligufalimab","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"5-Fluorouracile","genericName":"5-Fluorouracile","slug":"5-fluorouracile","phase":"marketed","mechanism":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Head and neck cancer","Pancreatic cancer"],"catalyst":""},{"name":"Carbo, 5FU, Cetuximab","genericName":"Carbo, 5FU, Cetuximab","slug":"carbo-5fu-cetuximab","phase":"phase_2","mechanism":"Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer","Head and neck cancer"],"catalyst":""},{"name":"Carboplatin, 5FU concomitant","genericName":"Carboplatin, 5FU concomitant","slug":"carboplatin-5fu-concomitant","phase":"phase_3","mechanism":"Carboplatin and 5-fluorouracil (5FU) work together as chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells.","indications":["Head and neck cancer (squamous cell carcinoma)","Locally advanced or metastatic head and neck cancer"],"catalyst":""},{"name":"Ethyol","genericName":"Ethyol","slug":"ethyol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ligufalimab","genericName":"Ligufalimab","slug":"ligufalimab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"concomitant cisplatin","genericName":"concomitant cisplatin","slug":"concomitant-cisplatin","phase":"phase_3","mechanism":"Cisplatin works by interfering with DNA replication, causing cell death in rapidly dividing cancer cells.","indications":["Ovarian cancer","Testicular cancer","Lung cancer","Bladder cancer","Stomach cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"marketed":2,"phase_2":1,"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}